

Greenblum and Bernstein P.L.C. 1950 Roland Clarke Place Reston VA 20191-1411

Date: August 24, 2007

To: Commissioner for Patents
U.S. Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450

<u>Subject: Misdirected Mail for US Patent</u> <u>Application No. 10/808,345</u>

The above-referenced firm is returning the enclosed Office Action.

Please note that, although the attached Form PTOL-90A was correctly printed with data related to our case, USSN 11/075,859, the attached Office Action for USSN 10/808,346 was incorrectly appended thereto.


It is noted that a correct Office Action has been received for our file 11/075,859.

We are not attorneys of record in USSN 10/808,345.

Signed







Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

gbpatent@gbpatent.com pto@gbpatent.com



l	· · · · · · · · · · · · · · · · · · ·				
, →——		Applicatio	n Nei Pe	Applicant(s)	
!			5	KRUGER ET AL.	
	Office Action Summary	Examiner	SEP 0 6 2007 W	Art Unit	
·		Carlic K. H	(1)	1617	
Period	The MAILING DATE of this communication app I for Reply	ears on the	coversbeam ith th	e correspondence add	lress
- E 2 - I - F	SHORTENED STATUTORY PERIOD FOR REPLY HICHEVER IS LONGER, FROM THE MAILING DAEXtensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. If NO period for reply is specified above, the maximum statutory period varieure to reply within the set or extended period for reply will, by statute than three months after the mailing tearned patent term adjustment. See 37 CFR 1.704(b):	ATE OF TH 36(a). In no eve will apply and will c, cause the appli	IS COMMUNICATI nt, however, may a reply be expire SIX (6) MONTHS fr cation to become ABANDO	ON. It is timely filed Tom the mailing date of this control (35 U.S.C. § 133).	
Status	•				
1)[2a)[3)[☐ This action is FINAL . 2b) ☐ This	action is no	for formal matters,		merits is
Dispo	sition of Claims				
5) 6) 7)	 ✓ Claim(s) 16-25 is/are pending in the application 4a) Of the above claim(s) is/are withdraw ☐ Claim(s) is/are allowed. ☐ Claim(s) is/are rejected. ✓ Claim(s) 16-25 is/are objected to. ☐ Claim(s) are subject to restriction and/o 	wn from cor			
Applic	cation Papers				
10)	 ☐ The specification is objected to by the Examine ☐ The drawing(s) filed on is/are: a) ☐ accomplication and accomplication and accomplication are request that any objection to the Replacement drawing sheet(s) including the correct ☐ The oath or declaration is objected to by the Examine 	epted or b)[drawing(s) be tion is require	e held in abeyance. ed if the drawing(s) is	See 37 CFR 1.85(a). objected to. See 37 CF	
Priorit	ty under 35 U.S.C. § 119				
12)	Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority document 2. Certified copies of the priority document 3. Copies of the certified copies of the priority document application from the International Bureau * See the attached detailed Office action for a list	s have beer s have beer rity docume u (PCT Rule	n received. n received in Applic nts have been rece e 17.2(a)).	eation No eived in this National S	Stage
1)	ment(s) Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing Review (PTO-948) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date		4) Interview Summ Paper No(s)/Ma 5) Notice of Inform 6) Other:	il Date	

Application/Control Number: 10/808,345

Art Unit: 1617

DETAILED ACTION

Election/Restrictions

- 1. This application contains claims directed to the following patentably distinct species:
 - (1) a single disclosed species of a compound of formula (I); and
 - (2) a single disclosed species of a cancer.

Applicant is required under 35 U.S.C. 121 to elect (1) a single disclosed species of a compound of formula (I) and (2) a single disclosed species of a cancer for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, claims 16-25 are generic.

It is noted that the species of compounds of formula (I) are structurally distinct and the search for each compound of formula (I) would represent an undue burden on the Office.

It is also noted that the species of cancer is distinct in design and the search for each cancer would represent an undue burden on the Office. The cancer may be selected from, for example, any solid tumor cancer or leukemia.

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which depend from or otherwise require all the limitations of an allowable generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).



Art Unit: 1617

Should applicant traverse on the ground that the inventions or species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions or species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C.103(a) of the other invention.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

A telephone call to the attorney is not required where: 1) the restriction requirement is complex, 2) the application is being prosecuted pro se, or 3) the examiner knows from past experience that a telephone election will not be made (MPEP § 812.01). Therefore, since this restriction requirement is considered complex, a call to the attorney for telephone election was not made.

Conclusion

2. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Carlic K. Huynh whose telephone number is 571-272-5574. The examiner can normally be reached on Monday to Friday, 8:30AM to 5:00PM.

Page 4

Application/Control Number: 10/808,345

Art Unit: 1617

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreenivasan Padmanabhan can be reached on 571-272-0629. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

ckh